DelveInsight’s, “Neuroendocrine tumors Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Neuroendocrine tumors pipeline landscape. It covers the Neuroendocrine Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Neuroendocrine Tumors Pipeline @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

• On June 18, 2026, Kineta Inc. initiated a phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and tumor response of the investigational drug KVA12123 alone and in combination with pembrolizumab in adults with relapsed or refractory advanced solid tumors. The study will be conducted in 4 parts: Parts A and B will focus on dose escalation (single-agent and in combination), and Parts C and D will focus on dose expansion (single-agent and in combination).
• On June 17, 2026- M.D. The Anderson Cancer Center conducted a clinical research study is to learn if olaparib, when given after treatment with cabazitaxel, carboplatin, and prednisone, can help to control aggressive variant prostate cancer (AVPC). The safety of these drugs will also be studied.
• DelveInsight’s Neuroendocrine Tumors pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Neuroendocrine Tumors treatment.
• The leading Neuroendocrine Tumors Companies such as Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.
• Promising Neuroendocrine Tumors Pipeline Therapies such as lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neuroendocrine Tumors Treatment Drugs

Neuroendocrine Tumors Overview

A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have a specific effect on the activity of other organs or cells in the body. Most NETs take years to develop and grow slowly. Neuroendocrine tumors may be functional or nonfunctional, depending on their hormone secretion. Functional NETs produce excess hormones, while nonfunctional tumors don’t produce hormones or enough of them to cause noticeable symptoms. Which hormone or hormones the cancer cells secrete depends on where the cancer develops.

Neuroendocrine Tumors Emerging Drugs Profile

• CAM2029: Camurus

CAM2029 is a long-acting subcutaneous depot of octreotide under development for the treatment of three rare diseases: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET) and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen device. Currently, the drug is in the Phase III stage of its development for the treatment of gastroentero pancreatic neuroendocrine tumors.

• AlphaMedix: Orano Med

AlphaMedix is a somatostatin receptor targeting peptide radiolabeled with 212Pb. Somatostatin receptors are overexpressed in most neuroendocrine tumors, a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract and pancreas, but can also occur in other tissues including thymus, lung, and other uncommon sites such as ovaries, heart, and prostate. After the promising results of the Phase I clinical trial launched early 2018, a Phase II was initiated late 2021 to assess the efficacy of Alphamedix in the treatment of neuroendocrine tumors. The study is currently recruiting patients in the US. Currently the drug is in Phase II stage of its clinical development.

• Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of its development.

The Neuroendocrine Tumors Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
• Neuroendocrine Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market

Explore groundbreaking therapies and clinical trials in the Neuroendocrine Tumors Pipeline @ New Neuroendocrine Tumors Drugs

Neuroendocrine Tumors Companies

Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.

Neuroendocrine tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Neuroendocrine Tumors Market Drivers and Barriers

Scope of the Neuroendocrine Tumors Pipeline Report

• Coverage- Global
• Neuroendocrine Tumors Companies- Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.
• Neuroendocrine Tumors Pipeline Therapies- lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.
• Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth Neuroendocrine Tumors Pipeline report today! @ Neuroendocrine Tumors Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Neuroendocrine Tumors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. RYZ101: RayzeBio, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Ramucirumab: Eli Lilly and Company
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ADCT-701: ADC Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Neuroendocrine Tumors Key Companies
21. Neuroendocrine Tumors Key Products
22. Neuroendocrine Tumors- Unmet Needs
23. Neuroendocrine Tumors- Market Drivers and Barriers
24. Neuroendocrine Tumors- Future Perspectives and Conclusion
25. Neuroendocrine Tumors Analyst Views
26. Neuroendocrine Tumors Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight